



OPEN ACCESS

EDITED BY
Fakhreddin Jamali,
Alberta Innovates–Health Solutions,
Canada

*CORRESPONDENCE
Abolghasem Jouyban,
ajouyban@hotmail.com,
jouyban@tbzmed.ac.ir

RECEIVED 13 September 2023
ACCEPTED 30 November 2023
PUBLISHED 18 December 2023

CITATION
Hashemzadeh N, Rahimpour E and
Jouyban A (2023), Corrigendum:
Applications of exhaled breath
condensate analysis for drug monitoring
and bioequivalence study of
inhaled drugs.
J. Pharm. Pharm. Sci 26:12042.
doi: 10.3389/jpps.2023.12042

COPYRIGHT
© 2023 Hashemzadeh, Rahimpour and
Jouyban. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Applications of exhaled breath condensate analysis for drug monitoring and bioequivalence study of inhaled drugs

Nastaran Hashemzadeh^{1,2}, Elaheh Rahimpour^{1,3} and
Abolghasem Jouyban^{1,4*}

¹Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran, ²Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran, ³Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, ⁴Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

KEYWORDS

exhaled breath condensate, bioequivalence, pharmacodynamic, pharmacokinetic, inhalers

A Corrigendum on Applications of exhaled breath condensate analysis for drug monitoring and bioequivalence study of inhaled drugs

by Hashemzadeh N, Rahimpour E and Jouyban A (2022). *J Pharm Pharm Sci*. 25:391–401. doi: 10.18433/jpps33121

In the original article, there was a mistake in **Table 1** as published. The order of the titles of the 2nd and 3rd columns have been reversed. The corrected form is that the title of the 2nd column is read as “EBC Conc.,” and that of the 3rd column as “Plasma Conc.”. The corrected column titles are marked with red font in the following Table.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

TABLE 1 An overview of drug concentrations in EBC and plasma samples, along with some details of the determination procedures.

Drug	EBC Conc.	Plasma Conc.	Analytical platform for EBC samples	LR ¹ /LOD ² for EBC samples	Significant feature	References
Alprazolam	NR ³	0.005–0.02 ppm	LC ⁴ –MS ⁵	2–18/1 pg. filter ¹	Sensitive	(30, 40)
Amikacin	(0.42–0.68) × 10 ⁻³ ppm	1.91–2.81 ppm	HPLC ⁶ –MS/MS	0.21–3,000/0.06 × 10 ⁻³ ppm	Quick and efficient	(43)
Amphetamine	NR ³	0.02–0.15 ppm	LC–MS	2–18/3 pg. filter ¹	Sensitive	(30, 40)
Aspirin	23.2–24.9 ppm	150–300 ppm	Colorimetry	10–250/4.1 ppm	High reliability	(41, 42)
Benzoylcegonine	NR ³	0.018–0.14 ppm	LC–MS	2–18/0.5 pg. filter ⁻¹	Sensitive	(30, 40)
Buprenorphine	NR ³	0.001–0.005 ppm	LC-MS/MS	NR ³ /2.5 × 10 ⁻³ ppm	Non-invasive and useful	(14, 40)
Buprenorphine	NR ³	0.001–0.005 ppm	LC–MS	2–18/2 pg. filter ⁻¹	Sensitive	(30, 40)
Carbamazepine	0.3–0.5 ppm	2–12 ppm	Spectrofluorimetry	0.2–20/0.08 ppm	Sensitive	(15, 40)
Cocaine	NR ³	0.1–0.3 ppm	LC–MS	2–18/2 pg. filter ⁻¹	Sensitive	(30, 40)
Codeine	NR ³	0.025–0.25 ppm	LC-MS/MS	NR ³ /0.1 × 10 ⁻³ ppm	Non-invasive and useful	(14, 40)
Daclatasvir	0.048–0.992 ppm	0.052–0.852 ppm	Plasmon resonance	0.01–1.0/0.008 ppm	Low LOD, low cost, sensitive	(44, 45)
Daclatasvir	NR ³	0.052–0.852 ppm	Spectrofluorimetry	0.5–15 × 10 ⁻³ /0.12 × 10 ⁻³ ppm	Simple, fast and sensitive	(46, 45)
Deferiprone	0.06–0.17 ppm	5–25 ppm	Spectrofluorimetry	0.06–1.50/0.06 ppm	Simple, low EBC volume	(21, 47)
Diazepam	NR ³	0.2–2 ppm	LC–MS	2–18/1 pg. filter ⁻¹	Sensitive	(30, 40)
Doxorubicin	(48.9–203) × 10 ⁻³ ppm	0.006–0.09 ppm	Spectrophotometric	0.02–0.2/0.00416 ppm	Simple, sensitive and reliable	(24, 40)
2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine	NR ³	NR ³	LC-MS/MS	NR ³ /0.01 × 10 ⁻³ ppm	Non-invasive and useful	(14, 40)
Fentanyl	NR ³	0.005–0.3 ppm	LC-MS/MS	NR ³ /0.05 × 10 ⁻³ ppm	Non-invasive and useful	(14, 40)
Hydromorphone	NR ³	0.001–0.03 ppm	LC-MS/MS	NR ³ /1 × 10 ⁻³ ppm	Non-invasive and useful	(14, 40)
Hydrocodone	NR ³	0.01–0.1 ppm	LC-MS/MS	NR ³ /0.5 × 10 ⁻³ ppm	Non-invasive and useful	(14, 40)
Lamotrigine	0.592–0.771 ppm	3–15 ppm	Spectrophotometric	NR ³ /0.005 ppm	Quick visual detection	(28, 40)
Lamotrigine	0.55–1.19 ppm	3–15 ppm	Spectrofluorimetry	0.05–2.0/0.011 ppm	Sensitive and fast	(48, 40)
Meperidine	NR ³	0.1–0.8 ppm	LC-MS/MS	NR ³ /0.05 × 10 ⁻³ ppm	Non-invasive and useful	(14, 40)
Meropenem	Not detectable	25.5 ppm	UHPLCHR-MS	21,168 pg. filter ⁻¹ /NR ³	Non-invasive	(55, 56)
Methadone	NR ³	0.05–0.5 ppm	LC-MS/MS	NR ³ /0.5 × 10 ⁻³ ppm	Non-invasive and useful	(14, 40)
Methadone	0.16–1.06 ppm	0.05–0.5 ppm	Capillary electrophoresis	0.15–5 ppm/0.15 ppm	Simple, sensitive and accurate	(16, 40)
Methadone	23.6–275 pg.min ⁻¹	0.05–0.5 ppm	LC–MS–MS	100–2000/3 pg/sample	Feasible	(12, 40)
Methadone	(0.34–1.31) × 10 ⁻³ ppm	0.05–0.5 ppm	LC	0.5–10 × 10 ⁻³ /0.5 × 10 ⁻³ ppm	Simple and low cost	(23, 40)
Methadone	0.7–0.48 ppm	0.05–0.5 ppm	Capillary electrophoresis	0.3–5/0.3 ppm	Simple and fast	(26, 40)
Methadone	NR ³	0.05–0.5 ppm	LC–MS	2–18/0.5 pg. filter ⁻¹	Sensitive	(30, 40)
Methamphetamine	NR ³	0.01–0.05 ppm	LC–MS	2–18/1 pg. filter ⁻¹	Sensitive	(30, 40)
Methodrexate	(45.4–140.8) × 10 ⁻³ ppm	2.27 ppm	Spectrofluorimetry	20–998.8 × 10 ⁻³ /15.9 × 10 ⁻³ ppm	Simple, fast and accurate	(40, 49)
Metoprolol	NR ³	0.02–0.5 ppm	Spectrofluorimetry	5–100 × 10 ⁻³ /2.1–3.4 × 10 ⁻³ ppm	Simple, low-cost	(40, 50)
6-Acetyl morphine	NR ³	0.015–0.10 ppm	LC–MS	2–18/1 pg. filter ⁻¹	Sensitive	(30, 40)

(Continued on following page)

TABLE 1 (Continued) An overview of drug concentrations in EBC and plasma samples, along with some details of the determination procedures.

Drug	EBC Conc.	Plasma Conc.	Analytical platform for EBC samples	LR ¹ /LOD ² for EBC samples	Significant feature	References
Morphine	NR ³	0.01–0.15 ppm	LC–MS	2–18/1 pg. filter ⁻¹	Sensitive	(30, 40)
Morphine	(0.10–5.48) × 10 ⁻³ ppm	0.01–0.15 ppm	LC-MS/MS	NR ³ /0.1 × 10 ⁻³ ppm	Non-invasive and useful	(14, 40)
Morphine	(89–173) × 10 ⁻³ ppm	0.01–0.15 ppm	GC ⁷ -MS	NR ³ /2.1 × 10 ⁻³ ppm	Repeatable and stable	(20, 40)
Naloxone	NR ³	0.01–0.03 ppm	LC-MS/MS	NR ³ /0.25 × 10 ⁻³ ppm	Non-invasive and useful	(14, 40)
Naltrexone	NR ³	0.005–0.03 ppm	LC-MS/MS	NR ³ /0.5 × 10 ⁻³ ppm	Non-invasive and useful	(14, 40)
Oxazepam	NR ³	0.2–1.5 ppm	LC–MS	2–18/1 pg. filter ⁻¹	Sensitive	(30, 40)
Oxycodone	NR ³	0.02–0.05 ppm	LC-MS/MS	NR ³ /0.25 × 10 ⁻³ ppm	Non-invasive and useful	(14, 40)
Oxymorphone	NR ³	NR ³	LC-MS/MS	NR ³ /0.75 × 10 ⁻³ ppm	Non-invasive and useful	(14, 40)
Oxymorphone	(29–82) × 10 ⁻³ ppm	NR ³	GC-MS	NR ³ /1.5 × 10 ⁻³ ppm	Repeatable, and stable	(20, 40)
Paracetamol	1.12–4.68 ppm	2.5–25 ppm	Colorimetry	0.2–10.0/0.49 ppm	Specific and simple	(17, 40)
Phenobarbital	0.21–1.65 ppm	1–5 ppm	Spectrofluorimetry	0.1–10.0/0.024 ppm	Feasible, efficient and simple	(40, 51)
Phenobarbital	0.72–1.80 ppm	1–5 ppm	Spectrofluorimetry	0.01–8.0/0.006 ppm	Reliable and sensitive	(40, 52)
Phenytoin	0.013–0.13 ppm	5–20 ppm	Capillary electrophoresis	0.001–0.10/0.001 ppm	Selectivity	(40, 53)
Piperacillin	90 × 10 ⁻³ ppm	5–20 ppm	Microfluidic sensor	NR ³ /56 × 10 ⁻³ ppm	Versatile and low LOD	(39, 40, 54)
Piperacillin	45 pg	5–20 ppm	UHPLCHR ⁸ -MS	988–203,895/3,083 pg.filter ⁻¹	Non-invasive	(55, 56)
Propranolol	0.030 ppm	0.02–0.3 ppm	LC-MS/MS	5.6–224 × 10 ⁻³ ppm/NR ³	Simple, cheap and feasible	(31, 40)
Tazobactam	90 × 10 ⁻³ ppm	7.7–13.7 ppm	Microfluidic sensor	NR ³ /56 × 10 ⁻³ ppm	Versatile and low LOD	(39, 40, 54)
Tazobactam	45 pg	7.7–13.7 ppm	UHPLCHR ⁸ -MS	988–203,895/3,083 pg. filter ⁻¹	Non-invasive	(55, 56)
Tetrahydrocannabinol	NR ³	0.001–0.007 ppm	LC–MS	2–18/3 pg. filter ¹	Sensitive	(30, 40)
Tobramycin	(13.7–32.2) × 10 ⁻³ ppm	5–10 ppm	Colorimetry	1.0–50.0 × 10 ⁻³ /0.5 × 10 ⁻³ ppm	Repeatable and low LOD	(18, 40)
Tobramycin	(21.4–41.6) × 10 ⁻³ ppm	5–10 ppm	UV spectroscopy	1.0–50.0 × 10 ⁻³ /(0.5 × 10 ⁻³ ppm)	Sensitive	(13, 40)
Tobramycin	(2.4–17.0) × 10 ⁻⁶ ppm	5–10 ppm	LC–MS	NR ³	Wide LR	(32, 40)
Tramadol HCl	NR ³	0.1–1 ppm	LC-MS/MS	NR ³ /0.5 × 10 ⁻³ ppm	Non-invasive and useful	(14, 40)
Salbutamol	(32.2–645.0) × 10 ⁻⁶ ppm	<0.01–0.02 ppm	LC–MS	NR ³	Wide LR	(32, 40)
Salbutamol sulfate	(89–173) × 10 ⁻³ ppm	<0.01–0.02 ppm	GC-MS	0.615–5/370 ppm	Wide LR and low LOD	(40, 57)
Valproic acid	(0.13–500) × 10 ⁻³ ppm	40–100 ppm	GC-MS	1.0–5.0 × 10 ⁻³ /0.08 × 10 ⁻³ ppm	Repeatable, wide LR	(27, 40)
Vancomycin	0.36–1.87 ppm	5–40 ppm	Spectrofluorimetry	0.1–8/0.06 ppm	Sensitive and low cost	(19, 40)
Verapamil	0.059–0.067 ppm	0.05–0.25 ppm	Spectrofluorimetry	0.02–12.0/0.008 ppm	Suitable and accurate	(29, 40)

LR¹: Linear range; LOD²: Limit of detection; NR³: Not reported; LC⁴: Liquid chromatography; MS⁵: Mass spectrometry; HPLC⁶: High-performance liquid chromatography; GC⁷: Gas chromatography; UHPLCHR⁸: Ultra-high-pressure liquid chromatography high-resolution mass spectrometry.